These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24501286)

  • 41. TCR repertoires of intratumoral T-cell subsets.
    Linnemann C; Mezzadra R; Schumacher TN
    Immunol Rev; 2014 Jan; 257(1):72-82. PubMed ID: 24329790
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Approval of the first TCR-based cell therapy.
    Singh N
    Mol Ther; 2024 Oct; 32(10):3195. PubMed ID: 39305896
    [No Abstract]   [Full Text] [Related]  

  • 44. Gene editing in T cell therapy.
    Zhang Y; Mu W; Wang H
    J Genet Genomics; 2017 Sep; 44(9):415-422. PubMed ID: 28967616
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy.
    Pizzitola I; Agostoni V; Cribioli E; Pule M; Rousseau R; Finney H; Lawson A; Biondi A; Biagi E; Marin V
    J Immunother; 2011; 34(6):469-79. PubMed ID: 21654519
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A dual role for genetically modified lymphocytes in cancer immunotherapy.
    Russo V; Bondanza A; Ciceri F; Bregni M; Bordignon C; Traversari C; Bonini C
    Trends Mol Med; 2012 Apr; 18(4):193-200. PubMed ID: 22230382
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Editorial: Cellular Therapies in Cancer.
    Rafei H; Mehta RS; Rezvani K
    Front Immunol; 2019; 10():2788. PubMed ID: 31827476
    [No Abstract]   [Full Text] [Related]  

  • 49. Recognition of carcinoembryonic antigen peptide and heteroclitic peptide by peripheral blood T lymphocytes.
    Brown ME; Miao H; McKee MD
    J Immunother; 2007 Apr; 30(3):350-8. PubMed ID: 17414326
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.
    Chmielewski M; Hombach AA; Abken H
    Gene Ther; 2011 Jan; 18(1):62-72. PubMed ID: 20944680
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Susceptibility of commonly used ferritin assays to the classic hook effect.
    Ranjitkar P; Turtle CJ; Harris NS; Holmes DT; Pyle-Eilola A; Maloney DG; Greene DN
    Clin Chem Lab Med; 2016 Feb; 54(2):e41-3. PubMed ID: 26351953
    [No Abstract]   [Full Text] [Related]  

  • 52. CAR T-cell design: a long road ahead.
    The Lancet Haematology
    Lancet Haematol; 2018 Mar; 5(3):e95. PubMed ID: 29499769
    [No Abstract]   [Full Text] [Related]  

  • 53. Targeting Mesothelin with Modified T Cells.
    Cancer Discov; 2015 Jul; 5(7):OF11. PubMed ID: 25971937
    [No Abstract]   [Full Text] [Related]  

  • 54. Biologics: Engineering T cells for customized therapeutic responses.
    Kingwell K
    Nat Rev Drug Discov; 2016 Nov; 15(12):819. PubMed ID: 27895334
    [No Abstract]   [Full Text] [Related]  

  • 55. Past and Future of the Molecular Characterization of the T Cell Repertoire: Some Highlights of Eli Sercarz's Contributions.
    Di Sante G; Tredicine M; Rolla S; Di Pino A; Ria F
    Crit Rev Immunol; 2020; 40(3):249-253. PubMed ID: 33389888
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cancer immunology community seeks better end points.
    Dolgin E
    Nat Rev Drug Discov; 2016 Nov; 15(12):807-809. PubMed ID: 27895329
    [No Abstract]   [Full Text] [Related]  

  • 57. Thermal Control of Engineered T-cells.
    Abedi MH; Lee J; Piraner DI; Shapiro MG
    ACS Synth Biol; 2020 Aug; 9(8):1941-1950. PubMed ID: 32786924
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genomic and epigenomic perspectives of T-cell exhaustion in cancer.
    Xia AL; Wang JC; Yang K; Ji D; Huang ZM; Xu Y
    Brief Funct Genomics; 2019 Mar; 18(2):113-118. PubMed ID: 29518177
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunotherapy takes aim at exhausted T cells.
    Dolgin E
    Nat Biotechnol; 2020 Jan; 38(1):3-5. PubMed ID: 31919438
    [No Abstract]   [Full Text] [Related]  

  • 60. Engineered T cell receptors and their potential in molecular medicine.
    Miles JJ; Silins SL; Burrows SR
    Curr Med Chem; 2006; 13(23):2725-36. PubMed ID: 17073624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.